News

November 1, 2017

Prof. Laurence Zitvogel’s Work Recognized with First ESMO Award for Immuno-Oncology

News

Prof. Laurence Zitvogel, an MD and PhD, received the first-ever ESMO Award for Immuno-Oncology in recognition of her innovative and widely recognized achievements in the field of cancer immunotherapy. The ESMO (European ... Read more

October 31, 2017October 31, 2017

Bristol-Myers Squibb Joins ORIEN Avatar Research Program for Cancer, M2Gen Announces

News

Bristol-Myers Squibb Company has joined the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program, a unique collaboration to explore new therapeutic options for the treatment of cancer, the health informatics solutions ... Read more

October 30, 2017

New Agenus Subsidiary AgenTus to Advance Cell Therapies for Cancer

News

The immuno-oncology company Agenus has launched a cell therapy subsidiary company, AgenTus Therapeutics, to advance new “living drugs,” or cell therapies, for people with cancer. AgenTus Therapeutics will use naturally-derived ... Read more

October 27, 2017October 30, 2017

First Patient Enrolled in Phase 1 Trial of INCB01158, Keytruda Combo for Solid Cancers

News

The first patient has been treated in a Phase 1 clinical trial evaluating a combination of INCB01158 (aka CB-1158) plus Keytruda (pembrolizumab) in patients with advanced solid tumors. The trial, ... Read more

October 26, 2017

Non-small Cell Lung Cancer Patients Survive Two Years After Receiving Tecentriq, Trial Shows

News

Patients with advanced non-small cell lung cancer whose first therapy was Genentech‘s Tecentriq (atezolizumab) survived a median of two years after treatment, according to long-term results of a Phase 2 clinical trial. The benefits ... Read more

October 25, 2017October 30, 2017

Potential Glioblastoma Therapy Safe to Deliver, Medicenna’s Interim Phase 2 Data Shows

News

A planned safety review of a Phase 2 trial evaluating MDNA55 to treat glioblastoma has shown that the drug, developed by Medicenna Therapeutics is safe to deliver precisely into a patient’s tumor, avoiding ... Read more

October 24, 2017

Last Participants Enrolled in Phase 2/3 Trial of NBTXR3 for Soft Tissue Sarcoma

News

Nanobiotix has completed patient enrollment in its Phase 2/3 trial (Act.In.Sarc), which is evaluating the safety and effectiveness of NBTXR3 in soft tissue sarcoma patients. The last patients are expected to initiate ... Read more

October 23, 2017October 23, 2017

Opdivo Not Recommended for Treating Urothelial Carcinoma in the UK

News

The U.K.’s National Institute for Health and Care Excellence (NICE) does not recommend Opdivo (nivolumab) treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC) after platinum-containing chemotherapy. NICE provides national guidance ... Read more

October 20, 2017October 20, 2017

Amgen and CytomX Therapeutics Announce Partnership for Immuno-Oncology Research

News

Amgen and CytomX Therapeutics have announced a partnership to jointly develop a new technology that uses antibodies to direct T-cells, a type of immune cell, to kill tumor cells. The approach, ... Read more

October 19, 2017October 19, 2017

$215 Million Public-Private Partnership Formed to Fight Cancer

News

The National Institutes of Health (NIH) partnered with PhRMA and nine of its member companies to establish the Partnership for Accelerating Cancer Therapies (PACT), a five-year immuno-oncology research collaboration totaling ... Read more